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I n t r o d u c t i o n.  Although the morbidity and mortality rates in invasive cervical carcinoma have been invariably high in
Poland, yet no national program of cervical cancer prevention has ever been introduced. We believe that in order to implement
a national program properly one should base on experience acquired in regional centers.
M a t e r i a l  a n d  m e t h o d s.  Under the West Pomeranian Program of Cervical Cancer Prevention mass cytological
screening (a total of 105,750 women) was performed in the West Pomeranian voivodship. The smears were evaluated in
a cytology lab where laboratory and diagnostic procedures are subject to internal quality control.
Re s u l t s.  In total, 735 pathological lesions (0.7%) were detected, including 711 intraepithelial lesions and 24 cases of invasive
carcinoma. The analysis of smear quality demonstrated a high percentage of suboptimal smears (59.5%), while 3.2% of
samples were unfit for any assessment. The rate of detection of intraepithelial lesions and carcinoma was much higher in good
quality smears as compared to suboptimal samples (0.90% vs. 0.65%).
C o n c l u s i o n s.  The effectiveness of cytological screening is affected by quality control including also the collection of
cytological smears. Therefore, before any nation-wide cervical cancer screening program is implemented the quality of
smears taken by gynaecologists has to be improved and both the Bethesda system of assessment of smears and the internal
quality control measures introduced in cytology laboratories participating in the program.
Zachodniopomorski program profilaktyki raka szyjki macicy
Wyniki I fazy badaƒ
W s t ´ p.  Mimo, ˝e wskaêniki zachorowalnoÊci i umieralnoÊci na raka inwazyjnego szyjki macicy w Polsce utrzymujà si´ od
wielu lat na wysokim poziomie, nie by∏o jak dotàd ogólnopolskiego programu profilaktycznego zwalczania raka szyjki maci-
cy. Uwa˝amy, ˝e dla w∏aÊciwej implementacji programu ogólnopolskiego mogà mieç znaczenie doÊwiadczenia lokalne.
M a t e r i a ∏  i m e t o d a.  W ramach Zachodniopomorskiego Programu Profilaktyki Raka Szyjki Macicy przeprowadzono
w województwie zachodniopomorskim przesiewowe badania cytologiczne u 105750 kobiet.. Oceny rozmazów dokonano
w pracowni cytologicznej, w której procedura laboratoryjna i diagnostyczna obj´ta jest wewn´trznà kontrolà jakoÊci.
W y n i k i.  ¸àcznie wykryto 735 zmian patologicznych (0,7%), w tym 711 zmian Êródp∏askonab∏onkowych (SIL) i 24 przypad-
ki raka inwazyjnego. Analiza jakoÊci rozmazów wykaza∏a wysoki odsetek rozmazów suboptymalnych (59,5%) i 3,2% rozma-
zów nie nadajàcych si´ do oceny. WykrywalnoÊç zmian Êródp∏askonab∏onkowych i raka by∏a znacznie wy˝sza w grupie rozma-
zów odpowiednich do oceny w stosunku do rozmazów suboptymalnych (0,90% vs 0,65%).
W n i o s k i.  1. Wa˝nym elementem wp∏ywajàcym na skutecznoÊç skryningu cytologicznego jest kontrola jakoÊci, obejmujàca
tak˝e sposób pobrania materia∏u cytologicznego. 2. Program profilaktyczny powinien byç koordynowany regionalnie, gdy˝: a)
rekrutacj´ kobiet do badaƒ profilaktycznych mo˝na powierzyç po∏o˝nym; b) mo˝na uzyskaç lepszà jakoÊç rozmazów przez za-
warcie w kontrakcie odpowiednich zapisów; c) Regionalne Kasy Chorych posiadajà dok∏adne i aktualne populacyjne bazy da-
nych.
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For the past 30 years the morbidity and mortality rates of
women with invasive cervical cancer in Poland have been
alarmingly high [1]. During this time, in numerous
countries a significant drop in cervical carcinoma
mortality has been achieved due to the introduction of
mass cytological screening programs [2, 3]. The number of
cytological gynecological tests performed annually in
Poland is estimated as approximately 2 million [4].
Nevertheless, no significant decrease in cervical cancer
mortality has been achieved, presumably because of the
low effectiveness of these tests. The low efficacy may
result from several factors, such as targeting inappropriate
age groups and lacking implementation of appropriate
quality control [5-8]. Nevertheless, it should be empha-
sized that there are centers in Poland which have been
actively performing cytological screening tests for years,
e.g. for example in Bialystok [9]. To date, there has been
no national program of cervical cancer prevention in
Poland. In 2001, the Maria Sklodowska-Curie Memorial
Cancer Centre and Institute of Oncology in Warsaw
initiated a Program of Model Screening for Breast and
Cervical Cancer in Poland (headed by Professor Zbigniew
Wronkowski) in which only 45 000 women were screened
in the 6 centers which participated in the program.
Below we present the results of Phase One of the
West Pomeranian Program of Cervical Cancer Prevention
in which a total of 105750 women were screened. We
believe that experience gained in the regional center may
be of help in future implementation of the nation-wide
screening program.
Material and method
The West Pomeranian Program of Cervical Cancer Prevention
was initiated in 2001. The program was based on mass preventive
cytological screening of women in the 20-59 age group. (In the
first year of the program, it was decided to include also women
above 59 years of age in order to detect invasive carcinomas in
this age group). In the West Pomeranian Province the population
of females aged 20-59 years is approximately 496,000. The
program has been carried out in the Cytology Lab of the
Department of Pathomorphology, Pomeranian Medical
University, which employs 9 cytology technicians and 3 specialists
in pathomorphology with long-term experience in cytodiagnosis.
The program was financed by the West Pomeranian Sick Fund
(WPSF). The principles of the program are presented in
Figure 1. In 2001, a total of 105750 cytological tests were
performed in women who visited a gynecologist upon their own
initiative following a vigorous regional media campaign. In 2002,
the Second Phase was commenced (active screening), where
the age range was restricted to 25-59 years. In the Second Phase
women from selected counties were invited to participate in
cytological testing by community midwives.
The smears were collected by gynecologists and stained
according to the Papanicolaou method using an automatic
stainer (Shandon). The results of the cytological tests were
described according to the Bethesda system. The diagnostic
procedures of the Cytology Lab were subject to internal quality
control, including re-screening of 10% of randomly selected
negative smears and consultations of all positive and suspicious
smears by a pathologist. The principles of quality control
observed in the Lab are in accordance with the recommenda-
tions formulated by European Union experts [7].
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Figure 1. The West Pomeranian Program of Cervical Cancer Prevention
Results
About 37% of all women examined were those below 30
years of age. (Figure 2). However, only 14.9% women in
the age group 31-40 showed up. In total, 735 (0.7%)
pathological lesions were detected, including 711
intraepithelial lesions and 24 cases of invasive carcinoma.
Figure 3 presents detectability rates of pathological
lesions depending on age. In women below 30 years of
age the high percentage of low grade intraepithelial
neoplasia (CIN I and/or HPV/SIL-LG) was found
(295/39223 women tested). In the age group below 25
years, CIN I cases were predominant. In the group aged
31-40 years, where the attendance rate was low, 44 cases
of high grade intraepithelial lesions (CIN II and
CINIII/SIL-HG) and three invasive carcinomas were
found. Thus the highest percentage of SIL-LG was noted
in young women and it gradually decreased with age.
Conversely, with growing age the number of invasive
carcinomas increased. Above 61 years of life invasive
carcinomas accounted for 23.5% pathologies, while in
women aged 31-60 years – for 4.8%.
The analysis of smear quality based on the Bethesda
system [10] revealed a very high percentage of smears of
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Figure 2. Recruitment of women in relation to age (n=105750)
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Figure 3. Percentage of epithelial abnormalities in relation to age
suboptimal quality (AII-59.9%) (Figure 4). Here the
largest group contained smears devoided of columnar
cells of the cervical canal. Smears unacceptable for
cytological evaluation (A III) constituted 3.2% of all the
samples. We noted a corelation between the quality
of the smears and the detectability rate of lesions
in cytological tests. In the group of appropriate smears
(A I), the detectability rate was 0.90%, while in the
group of suboptimal quality smears (A II) – only 0.56%
(Figure 5).
Discussion
Experience gained in numerous countries, and especially
in Scandinavia, indicates that the introduction of well
organized cytological screening programs results in
a significant decrease of the mortality rates due to cervical
cancer [7]. It has been observed that mass screening
programs should be carried out in an administratively
defined area (where population registers are available)
which is inhabited by at least 250,000 members of the
target population. These requirements have been met in
our program. The population of women that was
ultimately included into the study, was 496,000 and WPSF,
the co-organizer of the screening program, has at its
disposal the most current population data. In the first
phase of the program, the method of passive prevention
was employed, i.e. the tests were performed in all women
who reported to gynecologists following an intensive
campaign in the regional media and among gynecologists
whose services had been contracted by WPSF.
A recommended method of increasing the atten-
dance rate is based on an individual system of invitations
[7] that may be mailed [9], delivered by trained workers of
local administration [11], or by appropriately trained
health care personnel. In the second phase of our
program this role is to be assigned to community
midwives, because in the West Pomeranian province there
operates a network of community midwife practices, with
one midwife per 10,000 insurance holders. The database
maintained by WPSF and the identity PESEL number
have been utilized. The experience of other centers
indicates that other population databases may be subject
to errors involving the current domicile of individuals
recruited into a program. For example, during the
screening study carried out in the Podlaskie Province in
the years 1993-95, as many as 8% of addresses proved to
be erroneous [9].
European Union experts recommend cytological
gynecological screening tests to be performed in women
belonging to the 25-65 year age group [7]. The results of
population studies carried out in some countries, e.g. in
Iceland [3], point to the necessity of commencing
screening in 20-year old females and terminating the
program in women aged 60-64 years. Our experience
shows that in women below 25 years of age the predo-
minant pathology are low-grade intraepithelial lesions.
Since the majority of such lesions progress to higher CIN
grades over a several-year period (5-10 years), it seems
worthwhile to increase the lower age limit in screening
tests to 25 years. However, it should be stressed, that the
recommendations commonly advice screening in young
women (in the US as early as 18 years old) [12], although
it has been known that approximately a half of CIN I and
CIN II cases may spontaneously regress [13, 14]. In view
of the reported data and our experience in the course of
the West Pomeranian Program of Cervical Cancer Pre-
vention, the Second Phase of the Program will include
women aged 25-59 years.
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Figure 4. Quality of smears (n=105750)
Figure 5. Quality of smears in relation to percentage of detected
epithelial abnormalities (number of epithelial abnormalities/number of
cytological smears is give in brackets)
According to the UICC report maximum effecti-
veness of screening may be achieved when the program is
carried out in an organized way in women aged 25-60
years with the frequency of testing every 3-5 years [15]. In
addition, the European Union experts recommend that
screening programs involving healthy women and
performed more often than every 3 years should not be
financed out of public funds, since their effectiveness is
not significantly increased [7]. That is why in our program
the 3-year time interval has been accepted and the
decision involving more frequent testing has been
entrusted to the gynecologists.
A very important, although underestimated, element
that affects the effectiveness of screening programs is
quality control which includes the method of smear
collection, smear preparation and its microscopic
assessment. According to Solomon [16] more than 50% of
false negative results depends on the way the material
was collected and prepared. We have also reported the
relationship between the effectiveness in detecting
pathological lesions and smear quality [5, 11]. The
cytological diagnosis established according to the
Bethesda system contains information on the quality of
the smear. The analysis of Phase One results of the West
Pomeranian Program of Cervical Cancer Prevention
indicates that the detectability rate of pathological lesions
in smears the quality of which was appropriate for analysis
was 0.90%, while in suboptimal smears is was as low as
0.56%. It has been shown on the basis of comparative
studies, that cotton swabs should be abandoned in favor
of cytobrushes for smear collection [17-19]. To minimize
the number of false negative results, numerous countries
have initiated quality control procedures based on
recommendations formulated by European Union experts
[7]. In Poland such principles were developed by a team of
pathomorphologists headed by Professor A. Kulig and
published in 1999 [20].
The results we present here have been gathered in
Phase One of the Program. The Program was coordinated
on a regional level and based on financial support of the
Sick Fund, for which supporting preventive programs is
a statutory obligation. Prevention is also a significant
element of the National Health Fund. We have shown
that the effectiveness of cytological screening is affected
by the quality control. That also includes the method of
collection of cytological smears. Therefore, before any
nation-wide cervical cancer screening program is
implemented the quality of smears taken by gynaeco-
logists has to be improved and the Bethesda system of
assessment of smears together with the internal quality
control measures introduced in cytology laboratories
taking part in the program.
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